Published in Medical Letter on the CDC and FDA, March 19th, 2006
Eisai Medical Research, Inc., submitted the revised application on December 16, 2005.
ARICEPT, which is copromoted in the United States by Eisai, Inc., and Pfizer, Inc., is currently approved for treatment of mild-to-moderate Alzheimer disease.
ARICEPT is an acetylcholinesterase inhibitor and is believed to work by inhibiting the breakdown of acetylcholine, thereby increasing available levels of this chemical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.